A Randomized, Double-blind, Glucagon and Placebo-controlled Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of Single Escalating Doses of SAR438544 Administered by Subcutaneous Route in Healthy Subjects and Patients With Type 1diabetes Mellitus
Latest Information Update: 17 Sep 2021
At a glance
- Drugs SAR 438544 (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions; First in man
- Sponsors Sanofi
- 15 Sep 2017 Results presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes
- 13 Jun 2017 Results presented at the 77th Annual Scientific Sessions of the American Diabetes Association
- 29 Jul 2016 Status changed from recruiting to discontinued since the company has decided not to pursue the development of SAR438544 in diabetes, according to a Sanofi media release.